Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Alimta® (pemetrexed): Excipients and overfill
Alimta contains pemetrexed, mannitol, hydrochloric acid and sodium hydroxide. Each vial contains an excess of pemetrexed to facilitate delivery of label amount.
Alimta 100 mg vials contain:1
-
Pemetrexed disodium equivalent to 100 mg pemetrexed
active ingredient -
106.4 mg Mannitol
bulking agent -
Hydrochloric acid and/or sodium hydroxide
may have been added to adjust pH -
Water for Injection
Removed during freeze drying/lyophilization process
Alimta 500 mg Vials contain:1
-
Pemetrexed disodium equivalent to 500 mg pemetrexed
active ingredient -
500 mg Mannitol
bulking agent -
Hydrochloric acid and/or sodium hydroxide
may have been added to adjust pH -
Water for Injection
Removed during freeze drying/lyophilization process
Overfill
When reconstituted and used as directed, the vial will contain the product’s labeled amount (e. g. 500 mg or 100 mg) of usable/deliverable product.1
All Alimta vials are overfilled to ensure that the container “delivers” the label claim and to allow for any vial and syringe retention. The appropriate volume of diluent has to be used to ensure the usable/deliverable volume.1
The following overages are added for vial and syringe retention:1
-
8.5 % for Alimta 100 mg vials
-
2 % for Alimta 500 mg vials
Reconstitute 100-mg vials with 4.2 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.2
Reconstitute 500-mg vials with 20 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.2
Further dilution is required.2
Pemetrexed solutions are for single use only. Any unused medicinal product or waste material must be disposed of in accordance with local requirements.2
For precautions to be taken before handling or administering Alimta and for instructions on reconstitution and dilution of Alimta before administration, see section summary of product characteristics, section 6.6.2
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands
Date of Last Review: 17 May 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays